 Control of airway inflammation is the cornerstone of asthma management. The aim of the present pilot study was to assess whether, and in which magnitude, a leukotriene receptor antagonist LTRA added to a basic treatment of inhaled corticosteroids ICS long-acting betamimetics LABA might improve airway hyperresponsiveness and inflammation in well-controlled patients with asthma. 